PARIS, France, June 9, 2012-- Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin ...

Lantus can interact with several types of drugs, including metoprolol (Toprol XL), semaglutide (Ozempic), and olanzapine (Zyprexa). These interactions can lead to an increased risk of hypoglycemia or ...

Lantus (insulin glargine) is a brand-name subcutaneous injection that’s prescribed for diabetes. It’s used in adults and some children. The cost of the drug with and without insurance can depend on ...

Jumping into the multibillion-dollar market for biosimilar insulin products seemed like a no-brainer for Merck & Co., which is one of the world’s leaders in diabetes. But the company’s Lantus biosim ...

GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin glargine ...

PARIS/LONDON, June 18 (Reuters) - Shares in French drugmaker Sanofi-Aventis fell 4 percent on Friday after a small Italian study rekindled fears about a possible link between its Lantus diabetes drug ...

Eli Lilly and Company reported that its investigational diabetes treatment basal insulin peglispro (BIL) was more effective than Sanofi's Lantus (insulin glargine) at reducing hemoglobin A1c (HbA1c) ...

Sanofi ($SNY) and its top-selling Lantus may have bought some time last month with a legal wrench in Eli Lilly's ($LLY) spokes, but now Merck ($MRK) has bulldozed its ...

(Reuters) - U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus. Sanofi is ...

Here's some welcome news for diabetics dealing with the high price of insulin: The Food and Drug Administration has approved Mylan (MYL +0.00%) and Biocon's Semglee, which is essentially identical to ...

In updates from FDA, a copycat insulin is approved and final restrictions are lifted on a one-time blockbuster diabetes drug that all but disappeared from the market. It took awhile, but the end of ...

Mylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient in Sanofi’s Lantus blockbuster – have been dealt a blow. The FDA has issued a second complete ...